Last updated: February 20, 2026
Case Overview
UCB, Inc. filed suit against Hikma Pharmaceuticals USA Inc. in the District of Delaware, alleging patent infringement related to a biosimilar product. The complaint was filed on January 25, 2025, and centers on Hikma's development of a biosimilar to UCB's innovator drug, citing patent rights covering the biological and manufacturing processes.
Patent Claims and Alleged Infringement
UCB asserts that Hikma's biosimilar infringes multiple patents covering key aspects of the biologic. The patents include claims on the amino acid sequence, glycosylation profile, and formulation processes.
- Patents Asserted: UCB's patent portfolio includes at least three patents, issued between 2020 and 2023, with Expiration Dates spanning 2035-2040.
- Infringement Allegation: Hikma’s biosimilar, marketed under a tentative approval by the FDA, allegedly shares the key patented features, violating UCB’s exclusive rights.
Procedural Status
- Initial Filing: Complaint filed on January 25, 2025.
- Preliminary Motions: Hikma filed a motion to dismiss on March 15, 2025, arguing that UCB’s patents are invalid for obviousness and lack adequate written description.
- Discovery Phase: Began in June 2025, including depositions of key scientists and cross-party document exchanges.
- Recent Developments: As of October 2025, the court has scheduled a claim construction hearing for December 2025.
Key Legal Issues
Patent Validity
Hikma challenges the patents’ validity, asserting prior art references that allegedly render the claims obvious. UCB counters that the patents include non-obvious innovations concerning glycosylation and manufacturing specifics, supported by expert reports.
Patent Infringement
The core issue is whether Hikma’s biosimilar product infringes on the patent claims. UCB claims that the biosimilar’s amino acid sequence and production process are substantially similar to protected features.
Damages and Remedies
UCB seeks injunctive relief, monetary damages for patent infringement, and recall orders to prevent Hikma’s biosimilar market entry until patent issues are resolved.
Comparative Context
- The case mirrors recent biosimilar patent disputes, such as Amgen v. Hospira (Fed. Cir., 2020), where patent validity and scope significantly influenced market dynamics.
- The litigation timeline aligns with the typical 2-3 year patent dispute process in biosimilar cases, especially with complex patent claims and multiple challenges.
Strategic Considerations
- The outcome hinges on the court’s assessment of the patents' validity, particularly regarding the obviousness claims.
- Hikma’s pending FDA approval might expedite settlement negotiations if the court finds patents invalid or non-infringing.
- UCB’s enforcement of patent rights aims to delay market entry, impacting Hikma’s commercial plans and revenue projections.
Market Impact
- A favorable ruling for UCB could extend market exclusivity, delaying biosimilar competition.
- An adverse ruling or settlement might fast-track Hikma’s product launch and alter market share distribution.
Statistics & Timelines
| Event |
Date |
Key Details |
| Complaint Filed |
January 25, 2025 |
Patent infringement claim filed in Delaware District Court |
| Motion to Dismiss Filed |
March 15, 2025 |
Hikma challenge to patent validity |
| Discovery Phase Initiation |
June 2025 |
Exchange of documents, depositions commence |
| Claim Construction Hearing Scheduled |
December 2025 |
Court to interpret patent claims |
| Expected Trial Date (projection) |
Late 2026 |
Based on typical timelines for patent disputes in biosimilars |
Conclusion
UCB v. Hikma encapsulates the complexity in biosimilar patent litigation, emphasizing patent validity challenges and infringement claims. The case outcome will influence biosimilar market strategies and patent enforcement tactics.
Key Takeaways
- UCB asserts multiple patents protecting its biosimilar innovations, claiming Hikma's product infringes these rights.
- Hikma challenges patent validity, which could delay or prevent biosimilar market entry.
- The court is scheduled to interpret patent claims in December 2025; resolution may take until late 2026.
- The dispute exemplifies the legal landscape of biosimilar patent challenges, with significant commercial implications.
- Market dynamics depend heavily on the case’s outcome, affecting biosimilar competition and patent enforcement strategies.
FAQs
1. What are the main patents involved in this case?
UCB owns patents covering biological sequences, glycosylation, and production processes. The patents were issued between 2020 and 2023 with expiration dates from 2035 to 2040.
2. How strong is Hikma's invalidity challenge?
Hikma cites prior art references dating before the patents’ filing dates, alleging obviousness. UCB counters with evidence of non-obvious innovative features, but the court’s reliance on expert testimony will determine validity.
3. How does this case compare with other biosimilar disputes?
It mirrors disputes like Amgen v. Hospira, emphasizing patent validity and scope. The timeline and legal issues are characteristic of complex biosimilar patent litigation.
4. What are possible outcomes?
The court could uphold the patents, delaying Hikma’s biosimilar launch, or invalidate key claims, paving the way for market entry. Settlement negotiations may also result if resolution appears imminent.
5. What is the impact on the biosimilar market?
A positive ruling for UCB extends exclusivity, delaying biosimilar competition. Conversely, a ruling favoring Hikma accelerates biosimilar availability, impacting market share and pricing.
References
- [1] UCB, Inc. v. Hikma Pharmaceuticals USA Inc., 1:25-cv-00382, District of Delaware, filed January 25, 2025.
